Adding Immunotherapy to Chemotherapy for HER2-Negative Breast Cancer With a Very High Chance of Coming Back
This study will test if adding an immunotherapy drug to the usual chemotherapy treatment can improve outcomes for people with early-stage hormone receptor-positive (HR+), HER2-negative breast cancer that has a very high chance of coming back.